Piramal Pharma Solutions (PPS) announced the launch of its Xcelerate Integrated Solutions platform.
This platform will serve the increasing demand from pharmaceutical firms for preferred partnerships with organizations that can provide solutions across a range of verticals - drug discovery, drug substance, drug product, and clinical trial services.
The Xcelerate platform provides integrated solutions for orphan diseases, niche therapies, and fast track medicines, where the volume requirements are small, while also having the capacity and track record to address large volume needs of metabolic diseases and neuroscience therapies. The footprint of PPS allows customers to manufacture the final API or Drug product out of the West, while back integrating into starting materials and intermediates out of its sites in the East.
"We are excited to announce the launch of the Xcelerate Integrated Solutions™ platform. This platform is a result of the growing interest from our customers on structuring preferred relationships with global leaders such as Piramal who can offer end-to-end solutions, coupled with our desire to collaborate with strategic partners," Vivek Sharma, CEO, Piramal Pharma Solutions said.
PPS offers platform solutions from Discovery through Commercialization with 12 R&D and manufacturing locations across North America, Europe, and Asia. Over the past two years, PPS has integrated these services together to offer a seamless solution to customers. In parallel, PPS has also addressed gaps in its integrated offerings through both, acquisitions and internal investments. For example, in oncology therapeutics, where there is significant customer interest, Piramal now offers a unique platform that includes high potency API, fill-finish, and Antibody Drug Conjugation (ADC) solutions. The integrated capabilities are augmented by customized IT systems that allow for real time access on program progress.